China's CAS COVID-19 vaccine induces immune response in mid-stage tests
BEIJING (Reuters) - A candidate for a coronavirus vaccine developed by the Chinese Academy of Sciences (CAS) was shown to be safe in early and intermediate-stage studies and elicited immune responses, researchers said Tuesday.
A late-stage study of the ZF2001 vaccine, which CAS is developing with a unit of Chongqing Zhifei Biological Products, began in China last month. The aim is to recruit 29,000 people in China, Uzbekistan, Indonesia, Pakistan and Ecuador.
The candidate did not cause serious adverse events with common mild side effects such as injection pain, redness and swelling, researchers from the Chongqing Zhifei Department, CAS and other Chinese institutes said in an article published the Tuesday before the review. https://bit.ly/3nKZzt0
Scroll to continue with the content
Microsoft and Redis
Visit us for an exclusive one-day kick-off event.
Register for the event and see what you can do with Azure Cache for Redis.
The combined data from Phase 1 and Phase 2 studies included 950 healthy Chinese participants aged 18 to 59 years. Low and high dose versions were tested, and the Phase 2 study also tested two doses versus three doses for both the low and high dose versions.
The higher dose, given over three injections 30 days apart, did not induce an improved immune response compared to the lower dose, the paper says. The Phase 3 study will study the lower-dose version, which was given via three injections.
Neutralizing antibodies to the virus were detected in at least 93% of participants who received three shots in different groups. The levels of antibodies raised by vaccines were higher than in samples from patients who had recovered from the disease, the researchers said.
However, these antibody-based readings alone are insufficient to predict how effective ZF2001 will be in protecting people from the virus, the researchers said, warning that they may not yet be able to determine the duration of immune responses.
The vaccine also triggered moderate cell-based immune responses, a crucial part of the human immune system that works differently than antibodies.
ZF2001 is a vaccine against protein subunits in which a harmless piece of the SARS-CoV-2 virus is used instead of the entire germ.
Four other Chinese vaccines from Sinopharm, Sinovac Biotech and CanSino Biologics have also entered phase 3 clinical trials.
(Reporting by Roxanne Liu and Ryan Woo; Editing by Edwina Gibbs)
You should check here to buy the best price guaranteed products.
Fight Highlights: Martin "El Toro" Bravo vs. Andrew "The Beast" Whitney
Fight Highlights: Carlos "El Changuito" Calvo Calvo vs. Javier "Blair" Reyes
CG: ATL@SF - 9/17/21
France recalls envoys from U.S. and Australia
CG: OAK@LAA - 9/17/21
A’s vs. Angels Highlights